FibroBiologics

FibroBiologics Advances CYWC628 DFU Trial Manufacturing

HOUSTON, July 7, 2026 FibroBiologics, Inc. has announced the successful completion of the third manufacturing batch of its investigational...

By cGxPwire Editor
July 10, 2026

Bio-Pharma

FibroBiologics Doses First Patients in Phase 1/2 Trial of CYWC628 for Diabetic Foot Ulcers

HOUSTON, June 16, 2026 FibroBiologics announced that the first patients have been dosed in its ongoing Phase 1/2 clinical...

By cGxPwire Editor
June 17, 2026

Bio-Pharma

FibroBiologics Reports Durable Psoriasis Immunomodulation Data at SID 2026

HOUSTON, May 22, 2026 FibroBiologics, Inc. announced new preclinical data from its CYPS317 psoriasis program demonstrating durable immune modulation...

By cGxPwire Editor
May 27, 2026

Bio-Pharma

FibroBiologics to Spotlight Cell Therapy at H-SPAN Summit

Houston, Texas — February 10, 2026: FibroBiologics, Inc., a clinical-stage biotechnology company advancing fibroblast-based therapeutics, announced that its Chairman...